Vaccination is one of the most effective methods to prevent morbidity and mortality related to infectious diseases, yet there are many viral infections, such as Human Immunodeficiency Virus (HIV) and cytomegalovirus (CMV), for which durable, broadly cross-protective vaccines remain desperately needed. Although most of the focus in vaccine development has been on adaptive immune responses, natural killer (NK) cells are innate lymphocyte responders that rapidly and robustly kill virus-infected cells. Recent data has demonstrated that NK cells share features of adaptive immune responses-including the ability to respond more quickly and robustly upon a second challenge with the same antigen. Thus, they show great promise in establishing early control of infection in a vaccine or therapeutic setting where adaptive immune responses have proven to be too little and too late. Before this response can be elicited successfully, NK cell recognition of virus-infected cells must be understood at a detailed level. However, NK cells are a highly heterogeneous cell population, capable of a vast variety of functions and possessing a complex mosaic of surface receptors. The limits of fluorescence cytometry have prevented the simultaneous examination of all of these traits. To address this question, we propose the use of a novel technology, Cytometry by Time-Of-Flight (CyTOF). CyTOF can detect up to 40 cellular markers simultaneously, a considerable advance from the traditional fluorescence cytometry limit of 12-18. Thus, we will use CyTOF to comprehensively measure NK cell phenotype and functions during killing of virus-infected cells. We will define the specific populations of effector NK cells critical for responsesto HIV, influenza, and CMV by developing in vitro viral suppression assays in which NK cells from healthy donors recognize and kill autologous cells infected with these viruses. The highly parametric, deep profiling capabilities of CyTOF, applied to this specific, controlled interrogatio of antiviral NK cell function, will allow us to gain profound insight into which NK cells are activly recognizing and killing virus- infected cells. Results will be analyzed using a variety of complementary statistical techniques and dimensionality reduction algorithms. Once this analysis has defined specific subsets of NK cells involved in killing virus-infected cells, we will complement these findings using in vitro functional assays to define precisely how the NK cells are recognizing and killing the infected cells. These assays classically examine single receptors or functions, but will be adapted to simultaneously interrogate multiple receptors or functions in a combinatorial manner. Our innovative approach aims to understand which NK cell subsets to prime and which functions to stimulate in order to purposefully elicit an antiviral response in a vaccine or therapeutic setting. Our findings will therefore drive the development of innovative new approaches to vaccination.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
1DP2AI112193-01
Application #
8571323
Study Section
Special Emphasis Panel (ZRG1-MOSS-C (56))
Program Officer
Miller, Lara R
Project Start
2013-09-30
Project End
2018-08-31
Budget Start
2013-09-30
Budget End
2018-08-31
Support Year
1
Fiscal Year
2013
Total Cost
$2,386,599
Indirect Cost
$886,599
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Kronstad, Lisa M; Seiler, Christof; Vergara, Rosemary et al. (2018) Differential Induction of IFN-? and Modulation of CD112 and CD54 Expression Govern the Magnitude of NK Cell IFN-? Response to Influenza A Viruses. J Immunol 201:2117-2131
Wilk, Aaron J; Blish, Catherine A (2018) Diversification of human NK cells: Lessons from deep profiling. J Leukoc Biol 103:629-641
Paust, Silke; Blish, Catherine A; Reeves, R Keith (2017) Redefining Memory: Building the Case for Adaptive NK Cells. J Virol 91:
Herndler-Brandstetter, Dietmar; Shan, Liang; Yao, Yi et al. (2017) Humanized mouse model supports development, function, and tissue residency of human natural killer cells. Proc Natl Acad Sci U S A 114:E9626-E9634
Yao, Yi; Strauss-Albee, Dara M; Zhou, Julian Q et al. (2017) The natural killer cell response to West Nile virus in young and old individuals with or without a prior history of infection. PLoS One 12:e0172625
Vendrame, Elena; Fukuyama, Julia; Strauss-Albee, Dara M et al. (2017) Mass Cytometry Analytical Approaches Reveal Cytokine-Induced Changes in Natural Killer Cells. Cytometry B Clin Cytom 92:57-67
Strauss-Albee, Dara M; Liang, Emily C; Ranganath, Thanmayi et al. (2017) The newborn human NK cell repertoire is phenotypically formed but functionally reduced. Cytometry B Clin Cytom 92:33-41
Blish, Catherine A (2016) Natural Killer Cell Diversity in Viral Infection: Why and How Much? Pathog Immun 1:165-192
Strauss-Albee, Dara M; Blish, Catherine A (2016) Human NK Cell Diversity in Viral Infection: Ramifications of Ramification. Front Immunol 7:66
Hatton, Olivia; Strauss-Albee, Dara Marie; Zhao, Nancy Q et al. (2016) NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus. Front Immunol 7:607

Showing the most recent 10 out of 13 publications